ReviewCNS neuroscience & therapeutics2025
Histamine Modulation of the Basal Ganglia Circuitry in the Motor Symptoms of Parkinson's Disease.
Review in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neuroinflammation plays a crucial role in the pathogenesis of Parkinson's disease: a systematic review and meta-analysis of clinical and biomarker evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- The T Allele of the HNMT C314T Polymorphism Is Associated with a Reduced Risk of Idiopathic Parkinson's Disease in Mexican Patients.Biomedicines · 2026Article
- Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease.Journal of clinical laboratory analysis · 2026Article
- Progress in the study of ion channel function, mechanisms, and mathematical modeling in Parkinson's disease.iScience · 2026Review
- The potential role of aberrant microglial synaptic pruning in the neurodevelopmental pathogenesis of tourette syndrome.Frontiers in neuroscience · 2026Review
- Molecular Insights into Bromocriptine Binding to GPCRs Within Histamine-Linked Signaling Networks: Network Pharmacology, Pharmacophore Modeling, and Molecular Dynamics Simulation.International journal of molecular sciences · 2025Article
- Novel Pyrrolidinyl Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Autism, Mood Disorders and Schizophrenia.ACS medicinal chemistry letters · 2025Article
- Novel Azaindazole Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Schizophrenia, Autism, and Mood Disorders.ACS medicinal chemistry letters · 2025Article
- Microglial Histaminergic Signaling Promotes Interleukin-10 Production and Ameliorates Motor Dysfunction in Parkinson's Disease.Aging and disease · 2025Article
- Case Report: Deep cervical lymphovenous bypass for Parkinson's disease.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purpose of reviewParkinson's disease (PD) is characterized by dopaminergic system dysfunction that results from the degeneration of neurons in the substantia nigra. However, studies suggest that other neurotransmitters, especially histamine, may also play a role in the development of PD. RECENT
findingsNumerous studies show that histamine levels in the basal ganglia significantly change in PD pathology, correlating with motor symptoms observed in animal models of PD. Histamine activates H1R or H4R on microglia in the substantia nigra, triggering an inflammatory response and promoting dopaminergic neuron degeneration. Additionally, histamine modulates neuronal excitability and firing activity (firing rate and pattern) by activating H1R, H2R, or H3R on neurons in the basal ganglia nucleus, ultimately impacting normal motor behavior as well as motor symptoms in models of PD. SUMMARY: This review presents the role of histamine and its receptor ligands in the basal ganglia nuclei, along with downstream ion channels linked to histamine receptors that influence immune response, neuronal excitability, and firing activity in PD. It highlights their effects on neuronal firing and their connection to PD motor symptoms. Investigating new ligands targeting basal ganglia histamine receptors and associated ion channels may facilitate the development of novel treatments for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.